Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq.ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA.
For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com
Shared 2 months ago
47 views
Shared 2 months ago
370 views
Shared 3 months ago
37 views
Shared 3 months ago
62 views
Shared 3 months ago
199 views
Shared 4 months ago
90 views
Shared 5 months ago
79 views
Shared 5 months ago
363 views
Shared 8 months ago
66 views
Shared 9 months ago
168 views
Shared 9 months ago
33 views
Shared 1 year ago
260 views
Shared 1 year ago
100 views
Shared 1 year ago
140 views
Shared 1 year ago
398 views
Shared 2 years ago
452 views
Shared 2 years ago
197 views
Shared 2 years ago
4.3K views
Shared 2 years ago
849 views
Shared 2 years ago
369 views
Shared 2 years ago
299 views
Shared 2 years ago
361 views
Shared 2 years ago
498 views
Shared 2 years ago
454 views
Shared 3 years ago
277 views
Ensure regulatory-grade Safety profile of your lead compound | In Vitro & Genetic Toxicology #shorts
Shared 3 years ago
187 views
Shared 3 years ago
101K views
Shared 3 years ago
432 views
Shared 3 years ago
884 views
Shared 3 years ago
278 views
Shared 3 years ago
1.4K views